JP2019513801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513801A5 JP2019513801A5 JP2018554492A JP2018554492A JP2019513801A5 JP 2019513801 A5 JP2019513801 A5 JP 2019513801A5 JP 2018554492 A JP2018554492 A JP 2018554492A JP 2018554492 A JP2018554492 A JP 2018554492A JP 2019513801 A5 JP2019513801 A5 JP 2019513801A5
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide
- release
- pharmaceutical product
- unit dose
- dose pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 56
- 239000011570 nicotinamide Substances 0.000 claims 28
- 229960003966 nicotinamide Drugs 0.000 claims 28
- 235000005152 nicotinamide Nutrition 0.000 claims 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims 27
- 229940127557 pharmaceutical product Drugs 0.000 claims 27
- 239000008185 minitablet Substances 0.000 claims 21
- 230000003111 delayed effect Effects 0.000 claims 18
- 238000013268 sustained release Methods 0.000 claims 16
- 239000012730 sustained-release form Substances 0.000 claims 16
- 239000011159 matrix material Substances 0.000 claims 12
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 12
- 229960004963 mesalazine Drugs 0.000 claims 12
- 230000001419 dependent effect Effects 0.000 claims 9
- 239000002702 enteric coating Substances 0.000 claims 9
- 238000009505 enteric coating Methods 0.000 claims 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 210000001072 colon Anatomy 0.000 claims 4
- 210000003405 ileum Anatomy 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324415P | 2016-04-19 | 2016-04-19 | |
| US62/324,415 | 2016-04-19 | ||
| PCT/US2017/028063 WO2017184563A1 (en) | 2016-04-19 | 2017-04-18 | Oral pharmaceutical compositions of nicotinamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513801A JP2019513801A (ja) | 2019-05-30 |
| JP2019513801A5 true JP2019513801A5 (enExample) | 2020-05-28 |
| JP7021108B2 JP7021108B2 (ja) | 2022-02-16 |
Family
ID=59227843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554492A Active JP7021108B2 (ja) | 2016-04-19 | 2017-04-18 | ニコチンアミドの経口薬学的組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11622938B2 (enExample) |
| EP (1) | EP3445360B1 (enExample) |
| JP (1) | JP7021108B2 (enExample) |
| KR (1) | KR20180135020A (enExample) |
| CN (1) | CN109152772B (enExample) |
| AR (1) | AR108233A1 (enExample) |
| AU (1) | AU2017252407A1 (enExample) |
| BR (1) | BR112018071363A2 (enExample) |
| CA (1) | CA3021066C (enExample) |
| ES (1) | ES2848575T3 (enExample) |
| RU (1) | RU2738114C2 (enExample) |
| TW (1) | TW201739455A (enExample) |
| WO (1) | WO2017184563A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2861229T3 (da) | 2012-06-15 | 2021-01-18 | Conaris Res Institute Ag | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
| WO2015086838A2 (en) | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| HUE048488T2 (hu) | 2013-12-13 | 2020-07-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával |
| US20210236519A1 (en) * | 2020-01-30 | 2021-08-05 | Atoz Pharmaceuticals Pvt Ltd | Controlled release dosage forms of 5-aminosalicylic acid and process thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791458A (fr) | 1972-07-31 | 1973-05-16 | Merck & Co Inc | Produit microencapsule |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| JP3455544B2 (ja) | 1994-06-02 | 2003-10-14 | リガ ダン | 抗ストレス剤、抗機能障害剤および抗老化剤、ならびに該薬剤の製造法 |
| WO1998022096A1 (en) * | 1996-11-15 | 1998-05-28 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
| IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
| US6897205B2 (en) * | 2001-01-31 | 2005-05-24 | Roehm Gmbh & Co. Kg | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| MX2007008833A (es) * | 2005-01-21 | 2008-03-25 | Pharmanova Inc | Formulaciones farmaceuticas y metodos de uso. |
| EP1935422A1 (en) | 2006-12-20 | 2008-06-25 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Pharmaceutical composition comprising nicotinamide or nicotinic acid |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| US20110104282A1 (en) | 2008-04-25 | 2011-05-05 | Karolinska Institutet Innovations Ab | New Therapy of Treatment of the Irritable Bowel Syndrome |
| WO2010010579A1 (en) | 2008-07-19 | 2010-01-28 | Lupin Limited | Multiple unit dosage form of niacin |
| EP2367421A4 (en) | 2008-12-17 | 2013-03-13 | Altheus Therapeutics Inc | ORAL FORMULAS |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| AU2013229990B2 (en) | 2012-03-07 | 2017-07-06 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
| US20150164920A1 (en) | 2012-03-30 | 2015-06-18 | Laboratorios Del Dr. Esteve S.A. | Controlled release formulation comprising mesalamine |
| DK2861229T3 (da) | 2012-06-15 | 2021-01-18 | Conaris Res Institute Ag | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
| US20140178468A1 (en) | 2012-12-24 | 2014-06-26 | Ranbaxy Laboratories Limited | Multiparticulate extended-release composition of mesalamine |
| US9763887B2 (en) | 2013-03-15 | 2017-09-19 | Allergan Pharmaceuticals International Limited | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
| US10456389B2 (en) | 2013-06-14 | 2019-10-29 | Conaris Research Institute Ag | Extended release nicotinamide formulation |
| HUE048488T2 (hu) * | 2013-12-13 | 2020-07-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával |
| WO2015086838A2 (en) * | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| EP3154523B1 (en) | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
| US20160045442A1 (en) | 2014-08-13 | 2016-02-18 | Cadila Healthcare Limited | Stable pharmaceutical compositions of mesalamine |
| CN104257669A (zh) | 2014-09-25 | 2015-01-07 | 合肥平光制药有限公司 | 一种用于向肠道递送水杨酸类药物的口服给药组合物 |
| BR112018071370A2 (pt) | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de mesalazina |
-
2017
- 2017-04-18 TW TW106112905A patent/TW201739455A/zh unknown
- 2017-04-18 AU AU2017252407A patent/AU2017252407A1/en not_active Abandoned
- 2017-04-18 BR BR112018071363A patent/BR112018071363A2/pt not_active Application Discontinuation
- 2017-04-18 AR ARP170100995A patent/AR108233A1/es unknown
- 2017-04-18 US US16/094,654 patent/US11622938B2/en active Active
- 2017-04-18 CN CN201780029815.4A patent/CN109152772B/zh active Active
- 2017-04-18 RU RU2018137323A patent/RU2738114C2/ru active
- 2017-04-18 EP EP17733604.7A patent/EP3445360B1/en active Active
- 2017-04-18 CA CA3021066A patent/CA3021066C/en active Active
- 2017-04-18 JP JP2018554492A patent/JP7021108B2/ja active Active
- 2017-04-18 WO PCT/US2017/028063 patent/WO2017184563A1/en not_active Ceased
- 2017-04-18 ES ES17733604T patent/ES2848575T3/es active Active
- 2017-04-18 KR KR1020187033390A patent/KR20180135020A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513800A5 (enExample) | ||
| JP2017019858A5 (enExample) | ||
| JP2012153724A5 (enExample) | ||
| RU2744576C2 (ru) | Пероральные фармацевтические композиции месалазина | |
| JP2017532363A5 (enExample) | ||
| JP2019513801A5 (enExample) | ||
| JP2014533656A5 (enExample) | ||
| AU2013229990A1 (en) | Controlled-release solid dosage forms of mesalamine | |
| JP6237760B2 (ja) | 腸溶錠 | |
| JP7021108B2 (ja) | ニコチンアミドの経口薬学的組成物 | |
| KR20180108814A (ko) | 다이메틸 퓨마레이트를 포함하는 약제학적 비드 제형 | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| JP2008503540A5 (enExample) | ||
| JP2007530492A5 (enExample) | ||
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| JP2016504390A5 (enExample) | ||
| HK40005191B (en) | Oral pharmaceutical compositions of nicotinamide | |
| HK40005191A (en) | Oral pharmaceutical compositions of nicotinamide |